Emergent BioSolutions
EBS
#7956
Rank
โ‚ฌ0.32 B
Marketcap
6,38ย โ‚ฌ
Share price
-3.20%
Change (1 day)
0.34%
Change (1 year)

Revenue for Emergent BioSolutions (EBS)

Revenue in 2026 (TTM): โ‚ฌ0.55 Billion

According to Emergent BioSolutions 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ0.56 Billion. In 2025 the company made a revenue of โ‚ฌ0.60 Billion a decrease over the revenue in the year 2024 that were of โ‚ฌ0.97 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Emergent BioSolutions from 2004 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚ฌ0.55 B-8.14%
2025 โ‚ฌ0.60 B-38.37%
2024 โ‚ฌ0.97 B5.26%
2023 โ‚ฌ0.92 B-8.04%
2022 โ‚ฌ1.00 B-31.29%
2021 โ‚ฌ1.46 B25.06%
2020 โ‚ฌ1.17 B33.38%
2019 โ‚ฌ0.87 B42.4%
2018 โ‚ฌ0.61 B50.83%
2017 โ‚ฌ0.40 B24.47%
2016 โ‚ฌ0.32 B-8.74%
2015 โ‚ฌ0.35 B28.99%
2014 โ‚ฌ0.27 B49.37%
2013 โ‚ฌ0.18 B45.21%
2012 โ‚ฌ0.12 B-38.9%
2011 โ‚ฌ0.21 B-2.15%
2010 โ‚ฌ0.21 B31.29%
2009 โ‚ฌ0.16 B28.31%
2008 โ‚ฌ0.12 B1.95%
2007 โ‚ฌ0.12 B-4.43%
2006 โ‚ฌ0.13 B18.81%
2005 โ‚ฌ0.11 B79.24%
2004 โ‚ฌ61.55 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
โ‚ฌ55.65 B 9,703.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
โ‚ฌ57.81 B 10,083.96%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚ฌ38.82 B 6,738.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
Soligenix
SNGX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
โ‚ฌ82.43 M-85.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚ฌ0.76 M-99.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ15.25 B 2,586.28%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel